2552-P: Preclinical Proof of Concept of ZT009, a Novel Unimolecular Long-Acting GLP-1 and Amylin Receptor Agonist
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2552-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von YUYING ZHANG und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Combination of GLP 1 and amylin analogs has emerged as next generation therapeutics for the treatment of obesity. We developed ZT009, a novel, long-acting unimolecular GLP-1 and Amylin receptor agonist, aiming to provide better efficacious and convenient treatment for obesity. Here, we report preclinical data supporting its therapeutic potential.
Methods
In vitro activities of ZT009 on GLP-1 and amylin were assessed using a BHK cell line that overexpresses the human GLP-1 receptor, and a CHO cell line co-overexpressing the human amylin receptor-3 (AMY3R), respectively. In vivo tests were carried out in both lean rats and diet-induced obese (DIO) rats to demonstrate the pharmacological efficacy of ZT009 as compared to amycretin. The pharmacokinetic (PK) parameters were measured in rats, minipigs and monkeys.
Results
ZT009 is an engineered peptide conjugate comprising GLP-1 and amylin analogs linked via a peptide linker and acylated with a fatty acid for time-action extension. It demonstrated high solubility and stability at neutral pH. In cell-based assays, ZT009 was designed to enhance AMY3R activity by 5.1-fold compared to amycretin, maximizing beneficial metabolic effects. Additionally, it was designed to moderately reduce GLP-1 activity to 0.6-fold that of amycretin, thereby minimizing GI side effects, while maintaining a wide safety margin. In lean rats and DIO rats, ZT009 dose-dependently reduced body weight and food intake with effects exceeding those of amycretin at same dose. Importantly, ZT009 exhibited a significantly prolonged half-life and delayed Tmax across all species tested compared to amycretin, suggesting reduced peak-to-trough variability and enhanced GI tolerability in clinical translation.
Conclusion
These preclinical data demonstrate that ZT009 is a potent, long-acting dual GLP-1 and amylin receptor agonist with superior pharmacology and pharmacokinetic properties. ZT009 represents a promising next-generation candidate for obesity therapy, supporting further clinical development. Disclosure Y. Zhang: None. B. Wu: None. B. Zhang: None. X. Zhao: None. X. Chen: None. M. Wang: None. H. Jiang: None. P. Gao: None. S. Lin: None. X. Zhang: None. Y. Zhang: None.
Zitieren
APA
ZHANG, Y., WU, B., ZHANG, B., ZHAO, X., CHEN, X., WANG, M., JIANG, H., GAO, P., LIN, S., ZHANG, X., & ZHANG, Y. (2026). 2552-P: Preclinical Proof of Concept of ZT009, a Novel Unimolecular Long-Acting GLP-1 and Amylin Receptor Agonist. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2552-p
Vancouver
ZHANG Y, WU B, ZHANG B, ZHAO X, CHEN X, WANG M, et al. 2552-P: Preclinical Proof of Concept of ZT009, a Novel Unimolecular Long-Acting GLP-1 and Amylin Receptor Agonist. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2552-p
BibTeX
@article{ZHANG2026,
author = {ZHANG, YUYING and WU, BO and ZHANG, BAOCHANG and ZHAO, XINYU and CHEN, XU and WANG, MIAO and JIANG, HUI and GAO, PENG and LIN, SIMEI and ZHANG, XUJIA and ZHANG, YUANYUAN},
title = {2552-P: Preclinical Proof of Concept of ZT009, a Novel Unimolecular Long-Acting GLP-1 and Amylin Receptor Agonist},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2552-p}
}
EUVIMED